Ifosfamide-induced nephrotoxicity in oncological patients

• Autores: Quiroz-Aldave, JE, Durand-Vásquez, MDC, Chávez-Vásquez, FS, Rodríguez-Angulo, AN, Gonzáles-Saldaña, SE, Alcalde-Loyola, CC, Coronado-Arroyo, JC, Zavaleta-Gutiérrez, FE, Concepción-Urteaga, LA, Haro-Varas, JC, Concepción-Zavaleta, MJ
• Formato: artículo
• Fecha de Publicación: 2024
• Institución: Instituto Nacional de Enfermedades Neoplásicas
• Repositorio: INEN-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.inen.sld.pe:20.500.14703/399
• Enlace del recurso: https: //doi.org/10.1080/14737140.2023.2290196; https://hdl.handle.net/20.500.14703/399
• Nivel de acceso: acceso abierto
• Materia: drug-related side effects; adverse reactions; Fanconi syndrome; Ifosfamide; neoplasms; nephrogenic diabetes insipidus; https://purl.org/pe-repo/ocde/ford#3.02.21

Introduction: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. Areas covered: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Expert opinion: Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.